C3a receptor antagonist therapy is protective with or without thrombolysis in murine thromboembolic stroke
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Pharmacology"
DOI: 10.1111/bph.14989
Abstract: Intravenous thrombolysis (IVT) after stroke enhances C3a generation, which may abrogate the benefits of reperfusion. The C3aR antagonist SB290157 is neuroprotective following transient but not permanent middle cerebral artery occlusion (MCAo). SB290157 remains untested in… read more here.
Keywords: receptor antagonist; c3a receptor; therapy protective; thrombolysis ... See more keywords
Phage therapy as a protective tool against pathogenic bacteria: How far we are?
Sign Up to like & getrecommendations! Published in 2022 at "Current pharmaceutical biotechnology"
DOI: 10.2174/1389201024666221207114047
Abstract: Bacterial infections continue to jeopardize human and animal health, impacting millions of lives by causing significant deaths every year. The use of antibiotics remains the primary choice of therapy and has only been partly successful… read more here.
Keywords: phage therapy; therapy protective; bacteriophage therapy; therapy ... See more keywords